Medical directors of cardiac catheterization and EP labs receive three to four times the amount of money from pharmaceutical companies and device manufacturers as other interventional cardiologists in the same zip code, according to a JAMA Internal Medicine study.
Las Vegas’ Nevada Heart & Vascular Center agreed to pay $2.5 million this week to settle claims that its physicians referred patients for genetic testing in exchange for kickbacks from the testing companies, KTNV Las Vegas reported June 19.
An eight-day trial and two-hour jury deliberation has culminated in the conviction of Pennsylvania cardiologist Samirkumar J. Shah, who on June 14 was found guilty of two counts of healthcare fraud for falsely billing insurers for unnecessary angina treatments.
The American College of Cardiology is partnering with Chicago-based company Veradigm to assemble the largest-ever ambulatory chronic disease network in the U.S., comprising more than 250,000 clinicians and 100 million patients.
An updated cost-effectiveness analysis of evolocumab suggests that while treatment with the PCSK9 inhibitor may always be somewhat costly, it remains effective in hard-to-treat patients and its reduced list price meets cost-effectiveness thresholds across a range of CV events in patients with very-high-risk atherosclerotic CVD.
Prompted by a New York Times deep-dive into elevated death rates at North Carolina Children’s Hospital, North Carolina’s secretary of health on May 31 called for an investigation into the hospital’s pediatric heart surgery unit.